AQR Capital Management
CTKB icon

AQR Capital Management’s Cytek Biosciences CTKB Stock Holding History

AQR Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.99M Buy
912,342
+168,887
+23% +$797K ﹤0.01% 1893
2025
Q4 		$3.75M Sell
743,455
-276,435
-27% -$1.28M ﹤0.01% 1751
2025
Q3 		$3.54M Sell
1,019,890
-218,503
-18% -$820K ﹤0.01% 1656
2025
Q2 		$4.21M Buy
1,238,393
+585,116
+90% +$1.95M ﹤0.01% 1381
2025
Q1 		$2.62M Buy
653,277
+521,135
+394% +$2.7M ﹤0.01% 1467
2024
Q4 		$858K Buy
132,142
+52,236
+65% +$311K ﹤0.01% 1969
2024
Q3 		$443K Buy
79,906
+19,759
+33% +$112K ﹤0.01% 2229
2024
Q2 		$336K Buy
60,147
+40,240
+202% +$242K ﹤0.01% 2220
2024
Q1 		$134K Sell
19,907
-36,299
-65% -$287K ﹤0.01% 2310
2023
Q4 		$513K Buy
56,206
+17,167
+44% +$108K ﹤0.01% 1874
2023
Q3 		$215K Buy
39,039
+13,057
+50% +$105K ﹤0.01% 2119
2023
Q2 		$222K Buy
+25,982
New +$233K ﹤0.01% 2057
2022
Q4 		– Sell
-31,163
Closed -$459K – 2214
2022
Q3 		$459K Buy
+31,163
New +$405K ﹤0.01% 1821

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AQR Capital Management's CTKB Position: Q1 2026 in Review

AQR Capital Management increased its Cytek Biosciences (CTKB) stake by 23% in Q1 2026, buying an estimated $797K and bringing the position to 912,342 shares worth $3.99M. The position accounts for ﹤0.01% of the portfolio, ranked #1893.

AQR Capital Management first reported a position in CTKB in Q3 2022 and has held it in 13 quarters since. The position peaked at $4.21M in Q2 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • AQR Capital Management held 912,342 shares of Cytek Biosciences worth $3.99M as of Q1 2026.
  • AQR Capital Management bought 168,887 Cytek Biosciences shares in Q1 2026, an estimated $797K.
  • Cytek Biosciences made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #1893 holding.
  • AQR Capital Management first reported a position in Cytek Biosciences in Q3 2022 and has held it in 13 quarters since.
  • AQR Capital Management's Cytek Biosciences position peaked at $4.21M in Q2 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.